Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline


Autoria(s): SCALCO, Andreia Zavaloni; RONDON, Maria Urbana Pinto Brandao; TROMBETTA, Ivani Credidio; LATERZA, Mateus Camaroti; AZUL, Joao Batista Costa Carvalho Serro; PULLENAYEGUM, Eleanor Maria; SCALCO, Monica Zavaloni; KUNIYOSHI, Fatima Helena Sert; WAJNGARTEN, Mauricio; NEGRAO, Carlos Eduardo; LOTUFO-NETO, Francisco
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background Sympathetic hyperactivity is one of the mechanisms involved in the increased cardiovascular risk associated with depression, and there is evidence that antidepressants decrease sympathetic activity. Objectives We tested the following two hypotheses: patients with major depressive disorder with high scores of depressive symptoms (HMDD) have augmented muscle sympathetic nervous system activity (MSNA) at rest and during mental stress compared with patients with major depressive disorder with low scores of depressive symptoms (LMDD) and controls; sertraline decreases MSNA in depressed patients. Methods Ten HMDD, nine LMDD and 11 body weight-matched controls were studied. MSNA was directly measured from the peroneal nerve using microneurography for 3 min at rest and 4 min during the Stroop color word test. For the LMDD and HMDD groups, the tests were repeated after treatment with sertraline (103.3 +/- 40 mg). Results Resting MSNA was significantly higher in the HMDD [29.1 bursts/min (SE 2.9)] compared with LMDD [19.9 (1.6)] and controls [22.2 (2.0)] groups (P=0.026 and 0.046, respectively). There was a significant positive correlation between resting MSNA and severity of depression. MSNA increased significantly and similarly during stress in all the studied groups. Sertraline significantly decreased resting MSNA in the LMDD group and MSNA during mental stress in LMDD and HMDD groups. Sertraline significantly decreased resting heart rate and heart rate response to mental stress in the HMDD group. Conclusion Moderate-to-severe depression is associated with increased MSNA. Sertraline treatment reduces MSNA at rest and during mental challenge in depressed patients, which may have prognostic implications in this group. J Hypertens 27:2429-2436 (c) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

FAPESP[2002/02419-4]

CNPq[304304/2004-2]

CNPq[305159/2005-4]

CNPq[306931/2006-0]

American Heart Association

American Physiological Society

Espirito Santo Science and Technology Foundation

[06-15709Z]

Identificador

JOURNAL OF HYPERTENSION, v.27, n.12, p.2429-2436, 2009

0263-6352

http://producao.usp.br/handle/BDPI/22540

10.1097/HJH.0b013e3283310ece

http://dx.doi.org/10.1097/HJH.0b013e3283310ece

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

Relação

Journal of Hypertension

Direitos

restrictedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #depression #heart rate #mental stress #microneurography #sertraline #sympathetic nervous system #HEART-RATE-VARIABILITY #CORONARY-ARTERY-DISEASE #MAJOR DEPRESSION #MYOCARDIAL-INFARCTION #CATECHOLAMINE RESPONSES #SYSTEM ACTIVITY #BLOOD-PRESSURE #MENTAL STRESS #DISORDER #FAILURE #Peripheral Vascular Disease
Tipo

article

original article

publishedVersion